Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma.

ABSTRACT:

Background

The prognosis of diffuse intrinsic pontine glioma (DIPG) remains poor, with no drug proven to be effective.

Methods

Patients with clinically and radiologically confirmed, centrally reviewed DIPG, who had failed standard first-line therapy were eligible for this multicenter phase II trial. The anti-epidermal growth factor receptor (EGFR) antibody, nimotuzumab (150 mg/m(2)), was administered intravenously once weekly from weeks 1 to 7 and once every 2 weeks from weeks 8 to 18. Response evaluation was based on clinical and MRI assessments. Patients with partial response (PR) or stable disease (SD) were allowed to continue nimotuzumab.

Results

Forty-four patients received at least one dose of nimotuzumab (male/female, 20/24; median age, 6.0 years; range, 3.0-17

SUBMITTER: Bartels U 

PROVIDER: S-EPMC4201068 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature